LONG ACTING OCTREOTIDE IN PTS WITH DISSEMINATED NEUROENDOCRINE TUMORS

被引：0
|
作者：
Markovich, A. [1 ]
Emelianova, G. [1 ]
Gorbounova, V. [1 ]
Bruzgin, V. [1 ]
Orel, N. [1 ]
机构：
[1] NN Blokhin Russian Canc Res Ctr Ramn, Dept Chemotherapy, Moscow, Russia
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：382 / 382
页数：1
相关论文
共 50 条
  • [41] Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors
    Wang, Yuhong
    Wang, Wei
    Jin, Kaizhou
    Fang, Cheng
    Lin, Yuan
    Xue, Ling
    Feng, Shiting
    Zhou, Zhiwei
    Shao, Chenghao
    Chen, Minhu
    Yu, Xianjun
    Chen, Jie
    ONCOLOGY LETTERS, 2017, 13 (03) : 1165 - 1174
  • [42] An experience of two Croatian centers in the treatment of gastroenteropancreatic neuroendocrine neoplasms with long-acting octreotide treatment
    Belev, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S173 - S173
  • [43] Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey
    Falconi, Massimo
    Fazio, Nicola
    Ferone, Diego
    Versari, Annibale
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (18) : 2317 - 2324
  • [44] A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors
    Raj, Nitya
    Cruz, Elizabeth
    O'Shaughnessy, Sarah
    Calderon, Claudia
    Chou, Joanne F.
    Capanu, Marinela
    Heffernan, Olivia
    DeMore, April
    Punn, Sippy
    Le, Tiffany
    Hauser, Haley
    Saltz, Leonard
    Reidy-Lagunes, Diane
    JCO ONCOLOGY PRACTICE, 2022, 18 (09) : 677 - E1541
  • [45] Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study
    Castellano, Daniel
    Bajetta, Emilio
    Panneerselvam, Ashok
    Saletan, Stephen
    Kocha, Walter
    O'Dorisio, Thomas
    Anthony, Lowell B.
    Hobday, Timothy
    ONCOLOGIST, 2013, 18 (01): : 46 - 53
  • [46] Treatment of gastroenteropancreatic neuroendocrine tumors with octreotide LAR.
    Tomassetti, P
    Migliori, M
    Lalli, S
    Corinaldesi, R
    Gullo, L
    GASTROENTEROLOGY, 2000, 118 (04) : A526 - A526
  • [47] Study of the course of neuroendocrine tumors with 111In-octreotide
    Ramos, J
    Maraña, G
    Tabuenca, MJ
    Castejón, I
    Ayllón, LJ
    Berrocal, JO
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S356 - S356
  • [48] The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
    Ducreux, M
    Ruszniewski, P
    Chayvialle, JA
    Blumberg, J
    Cloarec, D
    Michel, H
    Raymond, JM
    Dupas, JL
    Gouerou, H
    Jian, R
    Genestin, E
    Hammel, P
    Rougier, P
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2000, 95 (11): : 3276 - 3281
  • [49] Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors
    Enzler, Thomas
    Fojo, Tito
    SEMINARS IN ONCOLOGY, 2017, 44 (02) : 141 - 156
  • [50] Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors
    Ricci, S
    Antonuzzo, A
    Galli, L
    Orlandini, C
    Ferdeghini, M
    Boni, G
    Roncella, M
    Mosca, F
    Conte, PF
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (04): : 412 - 415
12345